Introduction
Executive Summary
Interstitial Cystitis: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Certolizumab pegol: UCB
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
Gefapixant: Merck & Co
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
• Comparative Analysis
Drug name: Company name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
• Comparative Analysis
LYT 503: PureTech Health
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..

Inactive Products
• Comparative Analysis
Interstitial Cystitis Key Companies
Interstitial Cystitis Key Products
Interstitial Cystitis- Unmet Needs
Interstitial Cystitis- Market Drivers and Barriers
Interstitial Cystitis- Future Perspectives and Conclusion
Interstitial Cystitis Analyst Views
Interstitial Cystitis Key Companies
Appendix

List of Tables
Table 1 Total Products for Interstitial Cystitis
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Interstitial Cystitis
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Key Companies
• Merck & Co
• PureTech Health
• Teva Pharmaceutical Industries
• Integrative Therapeutics, Inc.
• Lipella Pharmaceuticals, Inc.
• Astellas Pharma
• Seikagaku Corporation
• UCB
• Alivio Therapeutics
• Urigen Pharmaceuticals
• PureTech Health